La Caixa Foundation promotes the first major European artificial placenta project
4 December, 2020
Signs that illuminate cancer inside the body
4 December, 2020
The firm hopes to have 20 million doses available in the US by the end of the year
The American pharmaceutical company Moderna assured this Thursday that the vaccine it has developed against covid-19 has the potential to provide prolonged immunity, and that it hopes to have 20 million doses ready for distribution in the United States this year, according to EFE.
The company specified that according to studies by the US National Institute of Allergy and Infectious Diseases, participants in the first phases of the vaccine's clinical trials retained "high levels of neutralizing antibodies" for three months after the first vaccine, and two months after the second.
no side effects
The study also notes that the vaccine has "the potential to provide long-lasting" immunity to the coronavirus, without causing significant side effects after two months.
"These interim Phase 1 data suggest that mRNA-1273, our COVID-19 vaccine candidate, can generate long-lasting neutralizing antibodies in all age groups, including older adults and the elderly," Moderna said in a statement.
In addition, he explained that he is confident that he will have 20 million doses of the vaccine available in the US by the end of the year, and that he hopes to have between 100 and 125 million doses available globally by the end of the first quarter of 2021.
Of them, between 85 and 100 million will be distributed in the US, and between 15 and 25 million in the rest of the world, according to the company.
The US Food and Drug Administration (FDA) could grant emergency authorization to Pfizer and Moderna in the middle of this month, which could begin a first phase of a vaccination campaign against covid-19 at the end of December, always within a prioritization process.
US authorities hope that in June there will be a wide distribution network and availability of the vaccine throughout the country, to begin immunizing the general population.
